NKT2152 is developed by Pfizer Inc..

What development phase is NKT2152 in?

NKT2152 is FDA-approved (marketed).

What is the generic name of NKT2152?

nkt2152 is the generic (nonproprietary) name of NKT2152.

Last reviewed 2026-04-20 · How we verify

NKT2152 (nkt2152)

Pfizer Inc. · FDA-approved discontinued Small molecule Quality 3/100

At a glance

Generic name	nkt2152
Sponsor	Pfizer Inc.
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver) (PHASE1, PHASE2)
A Study of NKT2152, a HIF2α Inhibitor, in Patients With Advanced Clear Cell Renal Cell Carcinoma (PHASE1, PHASE2)
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NKT2152 CI brief — competitive landscape report
NKT2152 updates RSS · CI watch RSS
Pfizer Inc. portfolio CI